Balloon and Mesh Catheter Ablation of Pulmonary Veins

Slides:



Advertisements
Similar presentations
Atrial Fibrillation Ablation: My personal experience
Advertisements

Ali Alsayegh, MD, FRCPC,FACC Consultant Cardiologist, Consultant Cardiac Electrophysiologist.
Christopher L. Fellows, MD, FACC, FHRS Virginia Mason Medical Center Seattle, Wa. Cardiac Arrhythmias 2015.
Atrial Fibrillation 2014 Christopher L. Fellows, MD, FACC, FHRS
Long-term Efficacy and Safety of Catheter Ablation for AF: What is the Evidence? AHA QCOR Washington DC D. George Wyse MD PhD May 20, 2010.
Atul Verma, MD FRCPC Cardiology/Electrophysiology Heart Rhythm Program, Division of Cardiology Southlake Regional Health Centre Newmarket, Ontario, Canada.
SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Marc Gillinov, M.D. For the CTSN Investigators.
Optimal Method and Outcomes of Catheter Ablation of Persistent AF: The STAR AF 2 Trial Atul Verma, Jiang Chen-yang, Tim Betts, John Radcliffe, Jian Chen,
SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Marc Gillinov, M.D. For the CTSN Investigators.
NILOFAR RAHMAN, MD AMIT KUMAR, MD. DEFINITION  A SVT with uncoordinated atrial activation with constant deterioration of atrial mechanical function 
Cardioversion of Atrial Fibrillation Clinical Issues Christopher Granger, MD Director, Cardiac Care Unit Duke University Medical Center December 2007.
Ablation for Paroxysmal Atrial Fibrillation (APAF) Trial Presented at The American College of Cardiology Scientific Session 2006 Presented by Dr. Carlo.
INTERVENTIONAL TREATMENT OF ATRIAL FIBRILLATION St. Mary’s Hospital February – August 2007.
Clinical Title Date Jaret Tyler, MD Clinical Cardiac Electrophysiologist Assistant Professor of Medicine Ohio State’s Heart and Vascular Center Atrial.
Treating Atrial Fibrillation Richard Schilling St Bartholomew's Hospital, Queen Mary’s University of London.
Katheterablatie van atriumfibrilleren Waar staan we? Lukas Dekker.
John R Onufer MD FHRS.  Paroxysmal(that which terminates spontaneously) Persistent Sustained > 7 days, or lasting < 7 days but requires pharmacologic.
Amr Kamal, M.D Alexandria Main University Hospital Alexandria- Egypt ECRA 2010.
Audit of ablation procedures for AF Barts and The London.
Atrial Fibrillation Ablation Cardiology Symposium December 6, 2004 Paul R. Steiner, M.D. Cardiac Electrophysiology.
11 New Advances in Atrial Fibrillation Ablation: Cryoballoon-Based Pulmonary Vein Isolation Ahmed F. Osman, MD, FACC FESC, FHRS, FASE Florida Heart Rhythm.
Atrial Fibrillation Dr Nidhi Bhargava 8/10/13.
Atrial Fibrillation Rate or rhythm control? Who should be anticoagulated? Other treatment strategies.
Atrial Fibrillation Andreas Stein Robert Smith, M.D. August 11, 2003.
Complications of Ablation of Atrial Fibrillation How to Prevent and to Treat Complications of Ablation of Atrial Fibrillation How to Prevent and to Treat.
Basic Mechanisms of Atrial Fibrillation Relative to Ablation Osama Diab MD, Cardiology Lecturer of Cardiology, Ain Shams Universitry-Cairo Consultant Electrophysiologist,
PSST 10819_11/2008 Arrhythmia in Practice Today ™ Content provided by Boston Scientific September 2008 Lessons in Lesions.
Catheter Ablation of Atrial Fibrillation: Who? How? How Good? John D. Day, M.D. Director, Utah Cardiovascular Research Institute Utah Heart Clinic Arrhythmia.
©2012 MFMER | slide-1 New methods and techniques in catheter ablation of atrial fibrillation Yong-Mei Cha, MD Mayo Clinic NCF Shenyang, 2014.
AF: Catheter Ablation Isolation of the 4 pulmonary veins Linear lesions to create additional lines of block 1.
Transcatheter ASD closure, sans X-rays Peter Ewert MD Robert Beekman MD.
AF Ablation: How has the Technique and Technology developed? Professeur Dipen Shah Responsable de l’Unité d’électrophysiologie, Hopital Cantonal de Geneve,
EGM-Guided Ablation: CFE, Ganglia, Rotors… ISHNE 2009 Atul Verma, MD FRCPC Staff Cardiologist, Electrophysiologist Southlake Regional Health Centre Newmarket,
Redo afib ablation John R Onufer MD FHRS
Catheter Ablation of AF Electrogram-based Approach
Asklepios Klink St. Georg, Hamburg
Atrial Fibrillation Ablation: Who and Why ?
Temporal Stability of the Esophageal Location by Computed Tomography Imaging in Patients Undergoing Repeat Catheter Ablation of Atrial Fibrillation Karuna.
SWEDMAF Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Carina Blomstrom-Lundqvist SWEDMAF Trial.
Catheter Ablation of Atrial Fibrillation in the Last 10 Years: Breakthroughs and Advances Dr. Feifan Ouyang Asklepios Klinik St. Georg Hamburg Sept. 19th,
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pulmonary Vein Stenosis Complicating Ablation for.
Date of download: 7/6/2016 Copyright © The American College of Cardiology. All rights reserved. From: Catheter-induced linear lesions in theleft atrium.
Catheter Ablation of Atrial Fibrillation by Roderick Tung, Eric Buch, and Kalyanam Shivkumar Circulation Volume 126(2): July 10, 2012 Copyright.
PULMONARY VEIN STENOSIS
Contemporary Atrial Fibrillation Management
OneShot™ Renal Denervation System
Atrial Fibrillation: When Should You Consider Ablation?
AF in 2014 Dr Stewart Healy.
Figure 1 Pulmonary vein anatomical locations
Regulatory Considerations for Coronary Drug Coated Balloons – FDA View
Volume 15, Issue 1, Pages (January 2018)
The State of the Art Mayo Clinic Proceedings
AF ablation with 3D mapping: our technique and results
(p for noninferiority = )
Volume 12, Issue 7, Pages (July 2015)
Catheter Ablation for the Cure of Atrial Fibrillation Study
Matthew C. Hyman et al. JACEP 2016;j.jacep
Junaid A.B. Zaman et al. JACEP 2017;3:
ΝΟΣΟΣ ΤΑΧΥΒΡΑΔΥΚΑΡΔΙΑΣ: ΕΜΦΥΤΕΥΣΗ ΒΗΜΑΤΟΔΟΤΗ Η ΚΑΤΑΛΥΣΗ ΚΟΛΠΙΚΗΣ ΜΑΡΜΑΡΥΓΗΣ ; ΓΕΩΡΓΙΟΣ ΣΤΑΥΡΟΠΟΥΛΟΣ ΕΠ.Α ΚΑΡΔΙΟΛΟΓΟΣ ΓΝΘ ΙΠΠΟΚΡΑΤΕΙΟ.
Junaid A.B. Zaman et al. JACEP 2017;3:
David J Wilber MD Loyola University Chicago
Risk Factor Modification
Stavros Stavrakis et al. JACEP 2015;1:1-13
FDA Perspective Marco Cannella, PhD Senior Lead Reviewer
Successful transseptal puncture and cryoballoon ablation of symptomatic paroxysmal atrial fibrillation via jugular access in a patient with bilateral.
Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Catheter Ablation for Atrial Fibrillation/Atrial Flutter  Atul Verma, MD, FRCPC,
Vivek Y. Reddy et al. JACEP 2019;j.jacep
Vivek Y. Reddy et al. JACEP 2019;j.jacep
NICE 2014 Check pulse in patients presenting with:
Presentation transcript:

Balloon and Mesh Catheter Ablation of Pulmonary Veins ISHNE 2009 Atul Verma, MD FRCPC Cardiology/Electrophysiology Heart Rhythm Program, Division of Cardiology Southlake Regional Health Centre Newmarket, Ontario, Canada September, 2009

Disclosures Moderate Support (honoraria, speaking bureau, research) St Jude Medical International Medtronic Canada Biosense Webster Advisory Board

Objectives Better understand where we are in the application of balloon and mesh technologies for ablation of pulmonary veins Assess the benefits and limitations of both approaches To characterize the type of patient where this technology will be best applied

Case 1 50 year old male Past medical history – appendectomy, hypertension 5 years of symptomatic paroxysmal atrial fibrillation Episodes last 3-4 hours and occur every week Failed propafenone and sotalol LA size is 43 mm in PLAX view You book him for AF ablation

Case 1 Which of the following techniques would you use (assuming all were available to you)? A = point by point catheter-based PVI B = balloon-based cryoablation PVI C = mesh-based ablater PVI D = remote navigation based PVI

Case 2 50 year old male Past medical history – hypertension, hyperlipidemia, sleep apnea with CPAP 8 years of symptomatic paroxysmal atrial fibrillation which has become persistent Feels much better when cardioverted, but only lasts 2-3 weeks Failed sotalol, flecainide, and now dofetilide LA size is 48 mm in PLAX view You book her for AF ablation

Case 2 Which of the following techniques would you use (assuming all were available to you)? A = point by point catheter-based ablation B = balloon-based cryoablation C = mesh-based ablater D = remote navigation based ablation

Balloon-Based Ablation

Arctic Front - Cryoballoon Investigational Device Exemption (IDE) Study ongoing and is not available for sale in the United States. The information provided does not constitute any safety and effectiveness claims. The Arctic Front Cardiac CryoAblation Catheter is intended for the treatment of patients suffering from paroxysmal atrial fibrillation (PAF). Adjunct devices (Freezor MAX) can be used with Arctic Front in the treatment of PAF. Following this presentation US team will discuss how to deal with labeling issues 9

Arctic Front - Cryoballoon

Arctic Front - Cryoballoon 28mm 23mm

Arctic Front - Cryoballoon 1. Wire 2. Inflate 3.Occlude and Ablate

Lower Incidence of Thrombus Formation with Cryoenergy Vs Radiofrequency Catheter Ablation RF CRYO 4.3 mm 5.7 mm Area 25 mm² Vol 95 mm³ 5.3 mm Area 14 mm² Vol 49 mm³ 5.0 mm 76% 13% Incidence Of Thrombus Khairy et al. Circulation. 2003; 107:2045-50 Courtesy Peter Guerra, MD PGG 13

Effect on the Connective Tissue Matrix and Thrombogenicity RF RF lesion at 1 week (Canine model) +70°C - 50W • 60 seconds Cryo Cryolesion at 1 week (Canine model) -75°C • 1 x 4 minutes Less thrombogenic. Less collateral damage? (no PV stenosis, esophagus?) More reversible lesion? Key Message Points: Parameters: Average Cryolesion 4mm tip -75°C 1 x 4 minutes Average RF lesion 4mm tip +70°C 50W 60 seconds In the canine model (1-week acute cryolesion): After myocyte death, the healing response is characterized a rapid fibrotic response This results in a non-conducting lesion that heals quickly and well This cryolesion demonstrates: Minimal thrombus An intact endothelial boundary The well-demarcated nature of cryolesions A lesion in which the process of fibrosis is complete This RF lesion demonstrates: Some thrombus Some hemorrhage An incomplete fibrosis process A disrupted endothelial boundary Khairy et al. Circulation. 2003; 107:2045-50 Courtesy Peter Guerra, MD 14

Complete Occlusion is Key Courtesy Marc Dubuc, MD

Occlusion is Key A) B) Contact with entire PV ostium Blood flow halted = better cooling Circumferential lesion with single application Courtesy Marc Dubuc, MD 16

Leak = Incomplete Lesions Courtesy Marc Dubuc, MD

Case Study: Cryoballoon

Optimizing Occlusion Incomplete LSPV occlusion with LSPV, gap at roof Incomplete LSPV occlusion with leak of contrast into the atrium (Guide wire in inferior branch) Courtesy Marc Dubuc, MD 19

ICE Monitoring for Leak balloon leak Courtesy Marc Dubuc, MD 20

Optimizing Occlusion Incomplete LSPV occlusion with LSPV, gap at roof Incomplete LSPV occlusion with leak of contrast into the atrium (Guide wire in superior branch) Courtesy Marc Dubuc, MD 21

Complete LIPV occlusion with no leak of contrast into the atrium Optimizing Occlusion LSPV, gap at roof Complete LIPV occlusion with no leak of contrast into the atrium Courtesy Marc Dubuc, MD 22

Cryoablation and Right Pulmonary Veins Phrenic nerve pacing: Beware phrenic nerve palsy LSPV, gap at roof Complete RIPV occlusion with no leak of contrast into the atrium and pacing the phrenic nerve with a quadripolar catheter Courtesy Marc Dubuc, MD 23

Inferior PVs can be a Challenge “Hockey stick” technique “Pull down” technique “Big loop” technique Chun, Kuck, EHJ 2009

Clinical Results - Cryoballoon Number of pts Type of AF Acute Success F/U (days) Outcomes Comments/ Complicat’n Chun, Kuck et al, 2009 (28 mm) 27 100% parox, lone AF 98% PVs isolated except 2 RIPVs 271 70% cure (TTM) 3 PNPs – recovered 0,28,384 d Van Belle et al, 2008 139 100% PVs w/ balloon & cath 457 59% cure (1,2 proc) 4 PNPs – recov 6 mo Malmborg et al, 2008 40 80% parox, 18% parox/persist 91% had PVI w/ ball & cath 270 45% cure off drug, 53% on 2 PNPs, 2 dysphagia Neumann et al, 2008 346 85% parox, 15% persist 97% had PVI w/ ball & cath Median 365 (76% >6mo) 74% parox, 42% persist, some loss f/u (7d Holter) 24 PNPs, mostly w/ 23 mm, resolve <1y Klein et al, 2008 21 100% parox 95% of PVs isolated 172 86% (Holter) 3 PNPs

Clinical Results Predominantly paroxysmal, lone AF population Most of these done by skilled operators Success rates of traditional catheter ablation 75%-90% after 1-2 procedures in this population Success rates seem a bit lower Follow-up duration is limited Risk of PNP – but most resolve within 6-12 mo Faster, shorter procedure

Level of Isolation – Ostial or Antral? Used smaller 23 mm balloon diameter. Reddy et al, Heart Rhythm 2008

Level of Isolation – Ostial or Antral? Used larger 28 mm balloon diameter. Van Belle et al, J Interv Card Electrophysiol 2009

Cardiofocus – Laser Balloon Diode laser system Endoscope viewer - reusable From Reddy et al, Heart Rhythm 2008

Cardiofocus – Laser Balloon Not much published data Abstract presented at AHA 2007 30 pts with paroxysmal AF Acute isolation achieved in 91% of PVs 70% AF-free 6 mo, 67% AF-free 12 mo 2 on antiarrhythmics (60% success off drugs) 3 adverse events (not specified) Circulation, Supplement II, Vol 116, No 16 October 16, 2007, 2440 pp II-536

HIFU Balloon High Frequency Focused Ultrasound Reflected off a saline gas interface Forward focused in a ring pattern

HIFU Balloon Nakagawa et al, JCE 2007 (n=27) 87% acute PV isolation, 59% AF-free at 12 months 1 phrenic nerve palsy Schmidt et al, Heart Rhythm 2007 (n=15) 89% acute PV isolation, 58% AF-free at 12 months 2 permanent phrenic nerve palsies US Pivotal Trial (n=240) Started Jan 2007, 25 enrolling centers Approx 69 patients enrolled – study halted May 2008 to investigate serious adverse events

Mesh Ablator

Bard HD – Mesh Ablator Catheter

Bard HD – Mesh Ablator Catheter 36 pole design – allows for detailed PV signal mapping Delivers RF energy to multiple poles simultaneously – temperature controlled Pulsed RF energy delivery – contiguous lesions, prevents overheating and char Does not occlude blood flow – mesh design

Bard HD – Mesh Ablator From Mansour et al, Heart Rhythm 2008

Positioning the Mesh Use fluoroscopy with PV angiography, signals (look for atrial and PV signals. From DeFillipo et al, JCE 2009 Can also use ICE or electroanatomical mapping system. From Mansour et al, HR 2008

RF Delivery Meissner et al, JCE 2009 Delivered unipolar, pulsed in 5 ms pulses and delivered in alternating fashion to half of the electrodes followed by the other half. Deliver max 80-100 W to a target temp of 55-60 C. Look at 4 thermocouples – if temp is target in 3 of 4, continue for 300 sec. If not, adjust position.

Clinical Results – Mesh Ablator Number of pts Type of AF Acute Success F/U (days) Outcomes Comments/ Complicat’n Mansour et al, 2008 20 100% parox, lone AF 63% of PVs isolated, rest req usual abl’n No longer term outcome No complic’ns DeFillipo et al, 2009 17 10 parox, 7 persistent All PVs isolated, but only 47% RIPV 330 64% in sinus on drugs Meissner et al, 2009 26 14 parox, 12 persistent 94% of PVs isolated 90 65% in sinus by symptoms Steinwender et al, 2009 97% of PVs isolated 3-6 mos 57-60% in sinus 1 tamponade On average, about 9-12 min RF required per PV. Average procedure duration is about 3-4 hours. Average fluoro time was about 31-42 mins.

Mesh Ablator Success rates not as high as balloon technology Procedural and fluoro times are longer Very small number of patients studied Larger trials are required

Summary Balloon and mesh based technologies are promising avenues At this point, balloon technologies are further ahead in success and procedural efficiency Results not quite as good as traditional ablation and mostly limited to pure paroxysmals Further clinical evaluation/trials required to assess where these will “fit” in therapeutic armamentarium